GSK Foresees Return To Emerging Markets Growth
The second quarter saw continued declines in GSK's China and wider emerging markets business, but CEO Andrew Witty expects a return to growth in these sectors over the remainder of the year.
You may also be interested in...
GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.
After a decade-long wait, China has finally approved its first HPV vaccine, GSK's Cervarix, handing a lead to the UK-based firm over its US competitor Merck in the world’s second largest pharma market. But with Chinese companies also vying for a slice of the pie, the battle is just beginning, and pricing will be a key element.
Offering deep price discounts in exchange for inclusion in reimbursement lists is never easy, given companies' need to balance expected benefits in volume gains with their international pricing systems and commercial pressures. But in China the underlying considerations are even more complex, as shown by the latest round of national price reductions for selected drugs.